Miho Kazui

1.5k citations

26 papers · 1.2k indexed · 1 hit paper · h-index 11

Cardiology and Cardiovascular Medicine top 2%
Pharmacology top 5%
Pharmacology top 1%
Endocrinology, Diabetes and Metabolism top 5%
Surgery

Co-authors: Atsushi Kurihara Katsunobu Hagihara Nagy A. Farid Toshihiko Ikeda Osamu Okazaki Yumi Nishiya Tomoko Ishizuka Steven Wrighton
Topics: Antiplatelet Therapy and Cardiovascular Diseases (11 papers)Pharmacogenetics and Drug Metabolism (9 papers)Inflammatory mediators and NSAID effects (9 papers)
Cited by: Internal Medicine Cardiology and Cardiovascular Medicine Pharmacology
Journals: Circulation Drug Metabolism and Disposition Bioorganic & Medicinal Chemistry Letters
Partner nations: Japan United States Germany

In The Last Decade

Miho Kazui

25 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite

2009 628 citations Miho Kazui, Yumi Nishiya et al. Drug Metabolism and Disposition profile →

Peers

Countries citing papers authored by Miho Kazui

Since Specialization

Citations

This map shows the geographic impact of Miho Kazui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miho Kazui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miho Kazui more than expected).

Fields of papers citing papers by Miho Kazui

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miho Kazui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miho Kazui. The network helps show where Miho Kazui may publish in the future.

Co-authorship network of co-authors of Miho Kazui

This figure shows the co-authorship network connecting the top 25 collaborators of Miho Kazui. A scholar is included among the top collaborators of Miho Kazui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miho Kazui. Miho Kazui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Physiologically Based Pharmacokinetic Modeling of Valemetostat to Inform Dose Recommendations When Coadministered With CYP3A /P‐gp Modulators 2025 ·Clinical and Translational Science ·Akiko Watanabe,Noriko Okudaira,(unknown),Miho Kazui,Masakatsu Kotsuma,Takako Shimizu,Yvonne Lau	0
2	Pharmacokinetics, metabolism, and excretion of [14C]-valemetostat in healthy male participants, and in vitro plasma protein binding 2025 ·Cancer Chemotherapy and Pharmacology ·Masaya Tachibana,(unknown),(unknown),Miho Kazui,Tomoko Ikeda,Takako Shimizu,Shin‐ichi Inaba,Malaz Abutarif	4
3	CYP2C8-Mediated Formation of a Human Disproportionate Metabolite of the Selective NaV1.7 Inhibitor DS-1971a, a Mixed Cytochrome P450 and Aldehyde Oxidase Substrate 2021 ·Drug Metabolism and Disposition ·Daigo Asano,(unknown),Hamim Zahir,Hideyuki Shiozawa,Yumi Nishiya,(unknown),Miho Kazui,Naotoshi Yamamura,(unknown),Takahiro Shibayama,Shinichi Inoue,(unknown),Toshiyuki Watanabe,(unknown),Nobuaki Watanabe,Kouichi Yoshinari	5
4	Identification of non-P450 enzymes involved in the metabolism of new drugs: Their significance in drug interaction evaluation and prodrug disposition 2019 ·Drug Metabolism and Pharmacokinetics ·Yumi Nishiya,Eiko Suzuki,Tomoko Ishizuka,Miho Kazui,(unknown),Daisuke Nakai	2
5	Discovery of a bicyclo[4.3.0]nonane derivative DS88790512 as a potent, selective, and orally bioavailable blocker of transient receptor potential canonical 6 (TRPC6) 2018 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Tsutomu Nagata,(unknown),A. Nakamura,Naoki Miyoshi,Miho Kazui,Ken Sakurai,(unknown)	24
6	Human Intestinal Raf Kinase Inhibitor Protein (RKIP) Catalyzes Prasugrel as a Bioactivation Hydrolase 2015 ·Drug Metabolism and Disposition ·Miho Kazui,Yuji Ogura,Katsunobu Hagihara,(unknown),(unknown)	8
7	Hepatic Microsomal Thiol Methyltransferase Is Involved in Stereoselective Methylation of Pharmacologically Active Metabolite of Prasugrel 2014 ·Drug Metabolism and Disposition ·Miho Kazui,Katsunobu Hagihara,Takashi Izumi,Toshihiko Ikeda,Atsushi Kurihara	14
8	Absorption, distribution, metabolism and excretion of loxoprofen after dermal application of loxoprofen gel to rats 2014 ·Xenobiotica ·(unknown),Miho Kazui,Atsushi Kurihara,Takashi Izumi	8
9	Glutaredoxin Is Involved in the Formation of the Pharmacologically Active Metabolite of Clopidogrel from Its GSH Conjugate 2012 ·Drug Metabolism and Disposition ·Katsunobu Hagihara,Miho Kazui,Atsushi Kurihara,Toshihiko Ikeda,Takashi Izumi	7
10	Glutaredoxin and Thioredoxin Can Be Involved in Producing the Pharmacologically Active Metabolite of a Thienopyridine Antiplatelet Agent, Prasugrel 2010 ·Drug Metabolism and Disposition ·Katsunobu Hagihara,Miho Kazui,Atsushi Kurihara,Kazuishi Kubota,Toshihiko Ikeda	10
11	The Intestine As an Important Contributor to Prasugrel Active Metabolite Formation In Vivo 2010 ·Drug Metabolism and Disposition ·Katsunobu Hagihara,Miho Kazui,(unknown),(unknown),(unknown),Takashi Izumi,Toshihiko Ikeda,Atsushi Kurihara	9
12	Biotransformation of Prasugrel, a Novel Thienopyridine Antiplatelet Agent, to the Pharmacologically Active Metabolite 2010 ·Drug Metabolism and Disposition ·Katsunobu Hagihara,Miho Kazui,Atsushi Kurihara,Haruo Iwabuchi,Minoru Ishikawa,Hiroyuki Kobayashi,Naoki Tanaka,Osamu Okazaki,Nagy A. Farid,Toshihiko Ikeda	23
13	A Possible Mechanism for the Differences in Efficiency and Variability of Active Metabolite Formation from Thienopyridine Antiplatelet Agents, Prasugrel and Clopidogrel 2009 ·Drug Metabolism and Disposition ·Katsunobu Hagihara,Miho Kazui,Atsushi Kurihara,(unknown),(unknown),Osamu Okazaki,Nagy A. Farid,Toshihiko Ikeda	97
14	Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs 2009 ·Xenobiotica ·Katsunobu Hagihara,Miho Kazui,(unknown),Takashi Nanba,(unknown),Makoto Takahashi,Atsushi Kurihara,Osamu Okazaki,Nazar Farid,T. Ikeda	30
15	Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolitebreakdown → 2009 ·Drug Metabolism and Disposition ·Miho Kazui,Yumi Nishiya,Tomoko Ishizuka,Katsunobu Hagihara,Nagy A. Farid,Osamu Okazaki,Toshihiko Ikeda,Atsushi Kurihara	628
16	Abstract 4020: A Possible Mechanism of Poorer and more Variable Response to Clopidogrel than Prasugrel 2008 ·Circulation ·Katsunobu Hagihara,Miho Kazui,(unknown),(unknown),Nagy A. Farid,Atsushi Kurihara	3
17	The Biotransformation of Prasugrel, a New Thienopyridine Prodrug, by the Human Carboxylesterases 1 and 2 2008 ·Drug Metabolism and Disposition ·Eric T. Williams,(unknown),G. Douglas Ponsler,(unknown),E.J. Perkins,Steven Wrighton,Kenneth J. Ruterbories,Miho Kazui,Nagy A. Farid	105
18	Comparison of Human Cytochrome P450 Inhibition by the Thienopyridines Prasugrel, Clopidogrel, and Ticlopidine 2008 ·Drug Metabolism and Pharmacokinetics ·Katsunobu Hagihara,Yumi Nishiya,Atsushi Kurihara,Miho Kazui,Nagy A. Farid,Toshihiko Ikeda	69
19	Anti-HIV-1 Activities and Pharmacokinetics of New Arylpiperazinyl Fluoroquinolones 2002 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),(unknown),(unknown),Miho Kazui,Nobuhiro Kobayashi,Tomoaki Komai,Masahiko Hagihara,Takashi Nishigaki,Aikichi Iwamoto,Tomio Kimura,(unknown),Makoto Yamashita	33
20	Rapid, real-time sampling of R-84760 in blood by in vivo microdialysis with tandem mass spectrometry 2000 ·Journal of Pharmaceutical and Biomedical Analysis ·Nobuhiro Kobayashi,Miho Kazui,Toshihiko Ikeda	6

About Miho Kazui

Miho Kazui is a scholar working on Pharmacology, Pharmacology and Cardiology and Cardiovascular Medicine, having authored 26 papers that have together received 1.2k indexed citations. Recurring topics across this work include Antiplatelet Therapy and Cardiovascular Diseases (11 papers), Pharmacogenetics and Drug Metabolism (9 papers) and Inflammatory mediators and NSAID effects (9 papers). The work is most often cited by research in Internal Medicine (144 citations), Cardiology and Cardiovascular Medicine (789 citations) and Pharmacology (293 citations). Miho Kazui has collaborated with scholars based in Japan, United States and Germany. Frequent co-authors include Atsushi Kurihara, Katsunobu Hagihara, Nagy A. Farid, Toshihiko Ikeda, Osamu Okazaki, Yumi Nishiya, Tomoko Ishizuka, Steven Wrighton, G. Douglas Ponsler and Eric T. Williams. Their work appears in journals such as Circulation, Drug Metabolism and Disposition and Bioorganic & Medicinal Chemistry Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact